3D Ex Vivo Human COPD Model Introduction

COPD Characterized by Airway Obstruction

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by a persistent decrease in airflow and affecting millions of people worldwide. The airways in the lungs of COPD patients become blocked due to a combination of factors, including chronic inflammation, mucus production, and structural changes in the airway walls. Chronic inflammation causes the walls of the airways to thicken and become less elastic, making it harder for air to pass through. The overproduction of mucus can also lead to blockage of the airways. In addition, structural changes in the airway walls, such as loss of elastic fibers and deposition of collagen, further narrow the airways and impede airflow. Currently, there is no cure for COPD and treatment options are limited. Creative Biolabs can provide a better 3D ex vivo human COPD model to help customers study the underlying mechanism of COPD and develop new treatments.

Fig.1 Microbiome Airway Inflammation and Mortality in COPD. (Dicker, 2021)

3D Ex Vivo Human COPD Model

As a promising preclinical disease model, the 3D ex vivo human COPD model is a second airway tissue sample extracted from a COPD patient and cultured in a three-dimensional (3D) environment. Since this model allows maintaining the structural and functional integrity of the diseased second airway. Targeting adrenergic receptors with Isoprenaline as an effect reference allows researchers to study the molecular mechanisms of COPD or test drug candidates for bronchodilation-promoting treatments in a more natural setting.

Fig.2 3D ex vivo human COPD model. (Creative Biolabs)

What are the Advantages of 3D Ex Vivo Human COPD Model?

• Preserved Cell-cell and cell-matrix interactions
  These effects cannot be adequately captured in 2D models, making the 3D ex vivo Human COPD Model a more physiologically relevant tool for studying COPD.
• Better mimic in vivo conditions
  The 3D ex vivo Human COPD Model preserves significant structural and functional changes in diseased airways, including airway obstruction, inflammation, and oxidative stress, making this model a more pathologically relevant tool for studying COPD.
• More suitable for drug screening
  By testing drugs on the 3D ex vivo Human COPD Model, researchers can identify potential therapeutic agents and assess their efficacy in a more physiologically relevant setting. This approach could help reduce the number of animal studies needed for drug development and speed up the translation of new treatments for COPD.
• Potential for patient-specific therapy
  By using a second airway sample from an individual patient, researchers can study the underlying mechanism of COPD in that patient. This approach could help identify patient-specific biomarkers and develop personalized treatments for each patient's specific disease mechanism.

In summary, the 3D ex vivo human COPD model has some advantages over traditional 2D cell culture models and animal models in studying COPD. If you have been searching for an optimal preclinical model to validate your bronchodilator candidate or study the molecular mechanisms of COPD, please contact us for more details about how we can promote your project. In addition, we can also provide 3D ex vivo human acetylcholine/carbachol model and 3D ex vivo human adrenoceptors-isoprenaline model for you to find the most suitable model.

Related Sections:

• Ex Vivo Secondary Airways (Healthy) Contractility Model
• Ex Vivo Secondary Airways (Diseased) Contractility Model
• Ex Vivo Tertiary or Lower Airways (Healthy) Model
• Ex Vivo Tertiary or Lower Airways (Diseased) Model
• Ex Vivo Tertiary or Lower Airways (Bronchodilation) Model